SCHEMBL6472016

SCHEMBL6472016

CC(C)Oc1cccc(N=C=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
ALDH1A3 P47895 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
HTT P42858 1/20 0.41
PARP10 Q53GL7 1/20 0.40
TRPA1 O75762 1/20 0.40
CYP3A4 P08684 1/20 0.40
CA2 P00918 1/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NSD2 O96028 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
F2 P00734 1/20 0.38
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6504742 0.87 CYP3A4 (0.38) RXRARXRBKMT2AMEN1GAA
SCHEMBL5796149 0.83 MIF (0.44) RXRARXRBALDH1A3KMT2AMEN1
SCHEMBL1569276 0.83 DRD1 (0.46) KMT2AMEN1HTTALDH1A1LMNA
SCHEMBL633675 0.82 MAPK1 (0.36) RXRARXRBKMT2AMEN1TRPA1
SCHEMBL29541540 0.80 HTR3E (0.53) KMT2AMEN1GAACYP3A4CA2
SCHEMBL23447 0.80 HTR3E (0.53) KMT2AMEN1GAACYP3A4CA2
SCHEMBL11533412 0.80 MAPK1 (0.40) KMT2AMEN1TRPA1CYP3A4LMNA
SCHEMBL29808710 0.80 TDP1 (0.44) KMT2AMEN1GAAPARP10TRPA1
SCHEMBL5104173 0.80 TDP1 (0.44) KMT2AMEN1GAAPARP10TRPA1
SCHEMBL9111062 0.80 ALDH1A3 (0.53) ALDH1A3KMT2APARP10TRPA1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-58079969-A None JP disclosed
US-6962926-B2 Antagonist of MCP-1 function, and compositions and methods of use thereof TELIK, INC. (US) 2005-11-08 US disclosed
WO-2005014600-A1 ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF TELIK, INC. (US) 2005-02-17 WO disclosed
US-20040198719-A1 Antagonist of MCP-1 function, and compositions and methods of use thereof SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2004-10-07 US disclosed
US-5527811-A CALCIUM- AND SUBSTANCE P RECEPTOR-ANTAGONIST ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-06-18 US disclosed
WO-1995011895-A1 N-BENZOYL-4-OXY/THIO-2-SUBSTITUTED PIPERIDINES AS SUBSTANCE-P RECEPTOR ANTAGONISTS CIBA-GEIGY AG (CH) 1995-05-04 WO disclosed
EP-0634402-A1 Isochinolinone derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1995-01-18 EP disclosed
WO-1993020099-A2 CCK AND/OR GASTRIN RECEPTOR LIGANDS FERRING B.V. (NL) 1993-10-14 WO disclosed
EP-0371240-B1 USE OF N-PHENYL-SUBSTITUTED OXAZINDIONES AS HERBICIDES AND N-PHENYL-SUBSTITUTED OXAZINDIONES AND SOME PROCESSES FOR THEIR PRODUCTION BAYER AG (DE) 1993-06-16 EP disclosed
US-5164498-A Herbicidal N-phenyl-substituted oxazinediones BAYER AKTIENGESELLSCHAFT (DE) 1992-11-17 US disclosed
EP-0371240-A1 Use of N-phenyl-substituted oxazindiones as herbicides and N-phenyl-substituted oxazindiones and some processes for their production BAYER AG (DE) 1990-06-06 EP disclosed
US-4402731-A Herbicidally active novel substituted tetrahydropyrimidinones NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1983-09-06 US disclosed
JP-S5879969-A O-PROPARGYL CARBAMATE IHARA CHEM IND CO LTD 1983-05-13 JP disclosed
EP-0058868-A1 Derivatives of tetrahydropyrimidinon, process for their preparation and herbicides containing those derivatives as active products NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1982-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198719-A1 Antagonist of MCP-1 function, and compositions and methods of use thereof CCR1, CCL11, CCL2 RXRA 771/4885RXRB 618/4885ALDH1A3 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.